Novo Nordisk stock sees biggest loss in more than 20 years on CagriSema results

Published On Dec 20, 2024, 11:09 AM

Novo Nordisk's recent announcement regarding its GLP-1 drug, CagriSema, showed an average weight loss of 22.7% in participants, which was below the expected 25%. This disappointing result led to a historic sell-off of Novo Nordisk's stocks, marking its largest loss in over 20 years, with shares falling more than 20%. The company still has ongoing trials for diabetic patients, but the current results have negatively impacted investor confidence. Meanwhile, competitor Eli Lilly benefited from the news, seeing its stock increase as analysts note that Lilly's competing drugs may dominate in the near future.

Read full article

Stock Forecasts

NVOView NVO chart on TradingView

Negative

The disappointing results for CagriSema have significantly dented investor sentiment towards Novo Nordisk, leading to a substantial drop in its stock price. With the competitive landscape becoming tougher due to Lilly's advancements in similar drugs, it is unlikely that Novo Nordisk will recover quickly in the next few months. Investors should proceed with caution and consider short-selling or avoiding investments in Novo Nordisk at this time.

Related News

Stock market today: Dow, S&P 500, Nasdaq rebound as inflation data improves

Dec 20, 2024, 11:09 AM

Stocks signaled another rough day of trading on Friday after the House of Representatives voted against a Trump-backed spending bill.

NVO
TSLA
FDX
NVDA
NKE

Stock market today: Dow, S&P 500, Nasdaq slide as government shutdown looms, inflation data improves but still sticky

Dec 20, 2024, 9:31 AM

Stocks signaled another rough day of trading on Friday after the House of Representatives voted against a Trump-backed spending bill.

NVO
XLK

Stock market today: Dow, S&P 500, Nasdaq futures sell-off as government shutdown looms, inflation data improves but still sticky

Dec 20, 2024, 8:53 AM

Stocks signaled another rough day of trading on Friday after the House of Representatives voted against a Trump-backed spending bill.

SPY
NVO
TSLA